drugset / Trial / NCT01037244
Treatment of Erectile Dysfunction I
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).
Timeline
- Start
- 2009-09
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Udenafil | Small molecule | 50 mg | Oral |
| Subject | Udenafil | Small molecule | 100 mg | Oral |
| Subject | Udenafil | Small molecule | 150 mg | Oral |